All In Biotech

Free tool

FAERS Monitor: Zynrelef Kit

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211988 or its brand name (Zynrelef Kit, Bupivacaine, Meloxicam). Reports on generic versions are filed under their own applications.

Reports

213

Serious

53

25% of reports

Hospitalization

14

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • wound dehiscence30
  • suture related complication18
  • procedural nausea17
  • seroma12
  • wound necrosis12
  • skin odour abnormal11
  • blister10
  • pain10
  • product odour abnormal10
  • nausea9
  • no adverse event9
  • drug ineffective8
  • post procedural drainage8
  • rash8
  • erythema7

Reports by year received

View as table
YearReports
20211
202291
202358
202419
202524
202620

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,946 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
post procedural drainageSignal85772.02865.938,331
suture related complicationSignal182582.31649.442,784
wound necrosisSignal122529.11448.927,155
procedural nauseaSignal172132.41344.433,398
seromaSignal12941.4541.810,255
wound dehiscenceSignal30884.6633.825,380
skin odour abnormalSignal11276.9155.62,747
product odour abnormalSignal1094.451.5832
blisterSignal1017.69.6141
no adverse eventSignal94.92.624
erythemaSignal73.41.69
rash81.80.92
pain101.60.92
nausea91.10.60
drug ineffective80.60.32

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.